Emerging applications of anticytokine vaccines

Expert Review of Vaccines

Volumn 7, Issue 10, 2008, Pages 1507-1517

  Delavallée, Laure ^b   Assier, Eric ^b   Semerano, Luca ^a,b   Bessis, Natacha ^b   Boissier, Marie Christophe ^a,b  

^a AVICENNE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Cytokine; Immunotherapy; Inflammatory disease; Monoclonal antibody; Vaccination

Indexed keywords

AUTOANTIBODY; CD4 ANTIGEN; CYTOKINE; CYTOKINE RECEPTOR; DENOSUMAB; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; NAKED DNA; NEUTRALIZING ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PLASMID DNA; RANTES; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACTIVE IMMUNIZATION; ALLERGIC DISEASE; ASTHMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHRONIC INFLAMMATION; CLINICAL TRIAL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MULTIPLE SCLEROSIS; MYOCARDITIS; NONHUMAN; OSTEOPOROSIS; PARASITOSIS; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; HUMANS; MICE; RATS; VACCINATION; VACCINES;

EID: 57349190608     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.10.1507     Document Type: Review

References (72)

1. Cohen S, Bigazzi PE, Yoshida T. Commentary. Similarities of T cell function in cell-mediated immunity and antibody production. Cell. Immunol. 12(1), 150-159 (1974).
2. Oppenheim JJ, Feldmann M. Introduction to the role of cytokines in innate host defense and adaptive immunity. In: Cytokine Reference, Volume 1: Ligands. Oppenheim JJ, Feldmann M (Eds). Academic Press, London, UK 3-20 (2000).
3. Baggiolini M. Reflections on chemokines. Immunol. Rev. 177, 5-7 (2000).
4. Krause I, Valesini G, Scrivo R, Shoenfeld Y. Autoimmune aspects of cytokine and anticytokine therapies. Am. J. Med. 115(5), 390-397 (2003).
5. Queen C, Schneider WP, Selick HE et al. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl Acad. Sci. USA 86(24), 10029-10033 (1989).
6. Chatenoud L. Monoclonal antibody-based strategies in autoimmunity and transplantation. Methods Mol. Med. 109, 297-328 (2005).
7. Zagury D, Le Buanec H, Bizzini B, Burny A, Lewis G, Gallo RC. Active versus passive anticytokine antibody therapy against cytokine-associated chronic diseases. Cytokine Growth Factor Rev. 14(2), 123-137 (2003).
8. Watanabe M, Uchida K, Nakagaki K et al. Anticytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett. 581(10), 2017-2021 (2007).
9. Bachmann MF, Dyer MR. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat. Rev. Drug Discov. 3(1), 81-88 (2004).
10. Tissot AC, Maurer P, Nussberger J et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled Phase IIa study. Lancet 371(9615), 821-827 (2008).
11. Delavallee L, Assier E, Denys A et al. Vaccination with cytokines in autoimmune diseases. Ann. Med. 40(5), 343-351 (2008).
12. Dalum I, Butler DM, Jensen MR et al. Therapeutic antibodies elicited by immunization against TNF-α. Nat. Biotechnol. 17(7), 666-669 (1999).
13. Tan GH, Wang CC, Huang FY, Wang H, Huang YH, Lin YY. Active immunotherapy of allergic asthma with a recombinant human interleukin-5 protein as vaccine in a murine model. Chin. Med. J. (Engl.) 120(17), 1517-1522 (2007).
14. Rohn TA, Jennings GT, Hernandez M et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol. 36(11), 2857-2867 (2006). • Efficiency of a vaccine in two experimental autoimmune inflammatory diseases.
15. Delavallee L, Le Buanec H, Bessis N et al. Early and long-lasting protection from arthritis in tumour necrosis factor α (TNFα) transgenic mice vaccinated against TNFα. Ann. Rheum. Dis. 67(9), 1332-1338 (2008). •• Detailed description of long-term efficacy of a vaccine and demonstration of reversibility of blockade.
16. Le Buanec H, Paturance S, Couillin I et al. Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine 25(41), 7206-7216 (2007).
17. Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur. J. Immunol. 36(11), 2868-2874 (2006).
18. Uyttenhove C, Arendse B, Stroobant V, Brombacher F, Van Snick J. Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur. J. Immunol. 34(12), 3572-3581 (2004).
19. Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19(2), 89-97 (1998).
20. Shen Y, Chen J, Zhang X, Wu X, Xu Q. Human TNF-α gene vaccination prevents collagen-induced arthritis in mice. Int. Immunopharmacol. 7(9), 1140-1149 (2007).
21. Youssef S, Wildbaum G, Maor G et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J. Immunol. 161(8), 3870-3879 (1998).
22. He X, Tsang TC, Zhang T, Luo P, Harris DT. Antigen epitope-expressing cytokines for DNA immunization. Vaccine 23(16), 1966-1972 (2005).
23. Falgarone G, Duclos M, Boissier MC. TNFα antagonists in rheumatoid arthritis patients seen in everyday practice. Joint Bone Spine 74(6), 523-526 (2007).
24. Boissier MC, Assier E, Falgarone G, Bessis N. Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine 74(4), 373-375 (2008).
25. Keffer J, Probert L, Cazlaris H et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10(13), 4025-4031 (1991).
26. Bloquel C, Denys A, Boissier MC et al. Intra-articular electrotransfer of plasmid encoding soluble TNF receptor variants in normal and arthritic mice. J. Gene Med. 9(11), 986-993 (2007).
27. Wildbaum G, Youssef S, Karin N. A targeted DNA vaccine augments the natural immune response to self TNF-α and suppresses ongoing adjuvant arthritis. J. Immunol. 165(10), 5860-5866 (2000).
28. Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108(3), 415-423 (2001).
29. Spohn G, Guler R, Johansen P et al. A virus-like particle-based vaccine selectively targeting soluble TNF-α protects from arthritis without inducing reactivation of latent tuberculosis. J. Immunol. 178(11), 7450-7457 (2007). • Vaccine against TNF designed with virus-like particles (VLPs).
30. Bizzini B, Achour A. "Kinoids": the basis for anticytokine immunization and their use in HIV infection. Cell. Mol. Biol. (Noisy-le-Grand) 41(3), 351-356 (1995).
31. Le Buanec H, Delavallee L, Bessis N et al. TNFα kinoid vaccination-induced neutralizing antibodies to TNFα protect mice from autologous TNFα-driven chronic and acute inflammation. Proc. Natl Acad. Sci. USA, 103(51), 19442-19447 (2006). •• Seminal description of the efficacy of a vaccine against TNF in acute and chronic models of inflammation.
32. Spohn G, Keller I, Beck M, Grest P, Jennings GT, Bachmann MF. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur. J. Immunol. 38(3), 877-887 (2008).
33. Bertin-Maghit SM, Capini CJ et al. Improvement of collagen-induced arthritis by active immunization against murine IL-1β peptides designed by molecular modelling. Vaccine 23(33), 4228-4235 (2005). • Report on a vaccine against a cytokine peptide.
34. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res. Ther. 7(1), 29-37 (2005).
35. Galle P, Jensen L, Andersson C et al. Vaccination with IL-6 analogues induces autoantibodies to IL-6 and influences experimentally induced inflammation. Int. Immunopharmacol. 7(13), 1704-1713 (2007).
36. Onodera S, Ohshima S, Tohyama H et al. A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. Arthritis Rheum. 56(2), 521-530 (2007). •• DNA vaccine targeted to the site of inflammation.
37. Goldberg R, Wildbaum G, Zohar Y, Maor G, Karin N. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL-27. J. Immunol. 173(2), 1171-1178 (2004).
38. Barnes DA, Tse J, Kaufhold M et al. Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model. J. Clin. Invest. 101(12), 2910-2919 (1998).
39. Youssef S, Maor G, Wildbaum G, Grabie N, Gour-Lavie A, Karin N. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J. Clin. Invest. 106(3), 361-371 (2000).
40. Goldberg R, Zohar Y, Wildbaum G, Geron Y, Maor G, Karin N. Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27. J. Immunol. 173(10), 6465-6471 (2004).
41. Wildbaum G, Karin N. Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-α) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis. Gene Ther. 6(6), 1128-1138 (1999).
42. Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1 α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J. Immunol. 155(10), 5003-5010 (1995).
43. Youssef S, Wildbaum G, Karin N. Prevention of experimental autoimmune encephalomyelitis by MIP-1α and MCP-1 naked DNA vaccines. J. Autoimmun. 13(1), 21-29 (1999).
44. Nabors GS, Farrell JP. Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses. Infect. Immun. 62(12), 5498-5504 (1994).
45. Yang G, Li L, Volk A et al. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J. Pharmacol. Exp. Ther. 313(1), 8-15 (2005).
46. Yang J, Torio A, Donoff RB et al. Depletion of eosinophil infiltration by anti-IL-5 monoclonal antibody (TRFK-5) accelerates open skin wound epithelial closure. Am. J. Pathol. 151(3), 813-819 (1997).
47. Hertz M, Mahalingam S, Dalum I et al. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J. Immunol. 167(7), 3792-3799 (2001).
48. Tan GH, Su JM, Wang CC et al. A recombinant DNA plasmid encoding the human interleukin-5 breaks immunological tolerance and inhibits airway inflammation in a murine model of asthma. Int. Arch. Allergy Immunol. 145(4), 313-323 (2008).
49. Zuany-Amorim C, Manlius C, Dalum I et al. Induction of TNF-α autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases. Int. Arch. Allergy Immunol. 133(2), 154-163 (2004).
50. Ma Y, Ma AG, Peng Z. A potential immunotherapy approach: mucosal immunization with an IL-13 peptide-based virus-like particle vaccine in a mouse asthma model. Vaccine 25(47), 8091-8099 (2007).
51. Bossu P, Neumann D, Del Giudice E et al. IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proc. Natl Acad. Sci. USA 100(24), 14181-14186 (2003).
52. Hauer AD, Uyttenhove C, de Vos P et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 112(7), 1054-1062 (2005).
53. Sonderegger I, Rohn TA, Kurrer MO et al. Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur. J. Immunol. 36(11), 2849-2856 (2006).
54. Delmas PD. Clinical potential of RANKL Inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J. Clin. Densitom. 11(2), 325-338 (2008).
55. Spohn G, Schwarz K, Maurer P, Illges H et al. Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J. Immunol. 175(9), 6211-6218 (2005). • Clear-cut effects of a VLP-designed vaccine in a model of osteoporosis.
56. Richard M, Grencis RK, Humphreys NE, Renauld JC, Van Snick J. Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris-infected mice. Proc. Natl Acad. Sci. USA 97(2), 767-772 (2000).
57. Bizzini B, Volpato I, Lachgar A, Cohen P, Gringeri A. IFN α kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS. Biomed. Pharmacother. 53(2), 87-89 (1999).
58. Carelli C, Halbreich A, Bernard J et al. Immunogenicity of combined anti-HIV and anti-suppressive vaccine preparations. Biomed. Pharmacother. 46(4), 149-153 (1992).
59. Gringeri A, Musicco M, Hermans P et al. Active anti-interferon-α immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS study). J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20(4), 358-370 (1999).
60. Salazar-Onfray F, Lopez MN, Mendoza-Naranjo A. Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev. 18(1-2), 171-182 (2007).
61. Rad FH, Le Buanec H, Paturance S et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc. Natl Acad. Sci. USA 104(8), 2837-2842 (2007). • Kinoid approach efficient in blocking angiogenesis.
62. Bequet-Romero M, Ayala M, Acevedo BE et al. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis 10(1), 23-34 (2007).
63. Casaco A, Diaz Y, Ledon N et al. Effect of an EGF-cancer vaccine on wound healing and inflammation models. J. Surg. Res. 122(1), 130-134 (2004).
64. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J. Clin. Oncol. 26(9), 1452-1458 (2008).
65. Waterston AM, Salway F, Andreakos E, Butler DM, Feldmann M, Coombes RC. TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br. J. Cancer 90(6), 1279-1284 (2004).
66. Waterston AM, Gumbrell L, Bratt T et al. Phase I study of TNFα autovaccine in patients with metastatic cancer. Cancer Immunol. Immunother. 54(9), 848-857 (2005).
67. Zagury D, Gallo RC. Anticytokine Ab immune therapy: present status and perspectives. Drug Discov. Today 9(2), 72-81 (2004).
68. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-β immunization in Alzheimer's disease. Brain Pathol. 14(1), 11-20 (2004).
69. Ma X, Chow JM, Gri G, Carra G et al. The interleukin 12 p40 gene promoter is primed by interferon γ in monocytic cells. J. Exp. Med. 183(1), 147-157. (1996).
70. Niethammer AG, Xiang R, Becker JC et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8(12), 1369-1375 (2002).
71. Onodera M, Nelson DM, Sakiyama Y, Candotti F, Blaese RM. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials. Acta Haematol. 101(2), 89-96 (1999).
72. Capini CJ, Bertin-Maghit SM, Bessis N et al. Active immunization against murine TNFα peptides in mice: generation of endogenous antibodies cross-reacting with the native cytokine and in vivo protection. Vaccine 22(23-24), 3144-3153 (2004).